EDGAR·FLOW

Alector, Inc. — Form 10-Q

Filed November 5, 2026 · analyzed by the Periodic Agent
10-Q ▲ Likely positive significance 78/100
What the filing says
Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, an engineered glucocerebrosidase enzyme replacement therapy for Parkinson's disease and neurodegeneration. Alector receives $100 million upfront payment, up to $1.17 billion in development/regulatory/commercial milestone payments, and tiered royalties on net sales. Genentech assumes all development, manufacturing, and commercialization responsibility; Alector retains ownership of its proprietary Alector Brain Carrier platform for use in its own pipeline.
Why this rating

Material deal for $115M company: $100M upfront equals 87% of market cap, plus $1.17B milestones; transforms cash runway to 2029 per press release. Significant but not transformational—retains platform IP, validates asset value.

Tradability signal
NO TRADE

No trade: positive news with only -1.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=382). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.16 ▼ 0.92%
at our read · unknown
$2.18
+10 min · unknown
$2.15 ▼ 1.38%
+30 min · unknown
$2.21 ▲ 1.38%
+1 hr · unknown
$2.19 ▲ 0.69%
+4 hrs · unknown
$2.28 ▲ 4.54%

The stock had already moved +0.93% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ALEC · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.